Green tea polyphenols as a natural tumour cell proteasome inhibitor

Inflammopharmacology

Volumn 16, Issue 5, 2008, Pages 208-212

  Dou, Q P ^a,b   Landis Piwowar, K R ^a,b   Chen, D ^a,b   Huo, C ^c,d   Wan, S B ^c,e   Chan, T H ^c,d  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^d MCGILL UNIVERSITY   (Canada)

^e OCEAN UNIVERSITY OF CHINA   (China)

Author keywords

Cancer prevention; Chemotherapy; Methylation; Molecular target; Prodrug; Proteasome inhibitors; Tea polyphenols

Indexed keywords

EPIGALLOCATECHIN; EPIGALLOCATECHIN GALLATE; GREEN TEA EXTRACT; POLYPHENOL DERIVATIVE; PROTEASOME INHIBITOR;

BREAST CANCER; CANCER INHIBITION; CANCER PREVENTION; DRUG BIOAVAILABILITY; DRUG INHIBITION; DRUG STABILITY; HUMAN; HUMAN CELL; METHYLATION; PRIORITY JOURNAL; REVIEW; TEA;

ANTICARCINOGENIC AGENTS; CATECHIN; METHYLATION; PROTEASOME ENDOPEPTIDASE COMPLEX; TEA; UBIQUITIN;

EID: 58149136828     PISSN: 09254692     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10787-008-8017-8     Document Type: Review

References (31)

1. Adams, J. (2002). Development of the proteasome inhibitor PS-341. Oncologist. 7, 9-16.
2. An, B., Goldfarb, R. H., Siman, R. and Dou, Q. P. (1998). Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ. 5, 1062-75.
3. Catley, L., Tai, Y. T., Chauhan, D., Anderson, K. C. (2005). Perspectives for combination therapy to overcome drug-resistant multiple myeloma. Drug Resist. Updates 8, 205-18.
4. Ciechanover, A. (1998). The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J. 17, 7151-60.
5. Ciechanover, A., Orian, A., Schwartz, A. L. (2000). Ubiquitin-mediated proteolysis: biological regulation via destruction. Bioessays 22, 442-51.
6. Dou, Q. P., Goldfarb, R. H. (2002). Bortezomib (millennium pharmaceuticals). IDrugs 5, 828-34.
7. Ferlay, J., Bray, F., Pisani, P., andParkin, D.M.: GLOBOCAN (2000). Cancer Incidence, Mortality and Prevalence Worldwide. In: IARC CancerBase. Version 1.0, IARCPress, Lyon, France (2001)
8. Fujiki, H (1999): Two stages of cancer prevention with green tea. J Cancer Res Clin Oncol 125, 589-97.
9. Goy, A., Younes, A., McLaughlin, P., Pro, B., Romaguera, J. E., Hagemeister, F. et al. (2005). Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 23, 667-75.
10. Groll, M., Heinemeyer, W., Jager, S., Ullrich, T., Bochtler, M., Wolf, D.H., Huber, R. (1999). The catalytic sites of 20S proteasomes and their role in subunit maturation: a mutational and crystallographic study. Proc. Natl. Acad. Sci. (USA) 96, 10976-83.
11. Gupta, S., Ahmad, N., Mohan, R.R., Husain, M. M andMukhtar, H (1999).: Prostate cancer chemoprevention by green tea: in vitro and in vivo inhibition of testosterone-mediated induction of ornithine decarboxylase. Cancer Res 59, 2115-20.
12. Hideshima, T., Richardson, P., Chauhan, D., Palombella, V. J., Elliott, P. J., Adams, J. and Anderson, K. C. (2001). The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61, 3071-6.
13. Jankun, J., Selman, S. H., Swiercz, R. andSkrzypczak-Jankun, E. (1997): Why drinking green tea could prevent cancer. Nature 387, 561.
14. Kane, R. C., Farrell, A. T., Sridhara, R. and Pazdur, R. (2006). United States food and drug administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin Cancer Res. 12, 2955-60.
15. Kazi, A., Smith, D. M., Daniel, K., Zhong, S., Gupta, P., Bosley, M. E. andDou, Q. P. (2002). Potential molecular targets of tea polyphenols in human tumor cells: significance in cancer prevention. In Vivo 16, 397-403.
16. Kazi, A., Wang Z., Kumar, N., Falsetti, S. C., Chan, T. H. and Dou, Q. P. (2004). Structure-activity relationships of synthetic analogs of (-)-epigallocatechin-3-gallate as proteasome inhibitors. Anticancer Res. 24, 943-54.
17. Kuhn, D. J., Lam, W. H., Kazi, A., Daniel, K. G., Song, S., Chow, L. M., Chan, T. H. and Dou, Q. P. (2005). Synthetic peracetate tea polyphenols as potent proteasome inhibitors and apoptosis inducers in human cancer cells. Front Biosci. 10, 1010-23.
18. Landis-Piwowar, K. R., Kuhn, D. J., Wan, S. B., Chen, D., Chan, T. H. and Dou, Q. P. (2005). Evaluation of proteasome-inhibitory and apoptosis-inducing potencies of novel (-)-EGCG analogs and their prodrugs. Int J Mol Med. 15, 735-42.
19. Landis-Piwowar, K. R., Huo, C. D., Chen, D., Cui, Q. C., Minic, V., Shi, G. Q. et al. (2007a) A Novel Pro-drug of the Green Tea Polyphenol (-)-Epigallocatechin-3-Gallate as a Potential Anti-Cancer Agent. Cancer Res. 67:4303-10.
20. Landis-Piwowar, K. R., Wan, S. B., Wiegand, R. A., Kuhn, D, J., Chan, T. H. and Dou, Q. P. (2007b) Methylation Suppresses the Proteasome-Inhibitory Function of Green Tea Polyphenols. J Cell. Physiol. 213, 252-60.
21. Li, B., Dou, Q. P. (2000). Bax degradation by the ubiquitin/proteasome- dependent pathway: involvement in tumor survival and progression. Proc. Natl. Acad. Sci. (USA) 97, 3850-5.
22. Lin, Y. L. and Lin, J. K. (1997: (-)-Epigallocatechin-3-gallate blocks the induction of nitric oxide synthase by down-regulating lipopolysaccharide- induced activity of transcription factor nuclear factor-kappaB. Mol Pharmacol 52, 465-72.
23. Lopes, U. G., Erhardt, P., Yao, R. and Cooper, G. M. (1997). p53-dependent induction of apoptosis by proteasome inhibitors. J Biol Chem. 272, 12893-6.
24. Naasani, I., Seimiya, H. andTsuruo, T. (1998): Telomerase inhibition, telomere shortening, and senescence of cancer cells by tea catechins. Biochem Biophys Res Commun 249, 391-6.
25. Nam, S., Smith, D. M. and. Dou, Q. P. (2001): Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem 276, 13322-30.
26. Okabe, S., Ochiai, Y., Aida, M., Park, K., Kim, S. J, Nomura, T. et al. (1999). Mechanistic aspects of green tea as a cancer preventive: effect of components on human stomach cancer cell lines. Jpn J Cancer Res 90, 733-9.
27. Pagano, M., Tam, S. W., Theodoras, A. M., Beer-Romero, P., Del Sal, G., Chau, V. et al. (1995). Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269, 682-5.
28. Perkins, N. D. (2000). The Rel/NF-kappa B family: friend and foe. Trends Biochem. Sci. 25, 434-40.
29. Richardson, P. G., Sonneveld, P., Schuster, M. W., Irwin, D., Stadtmauer, E. A., Facon, T. et al. (2005). Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 352, 2487-98.
30. Smith, D. M., Daniel, K. G., Wang, Z., Guida, W. C., Chan, T.-H. and Dou, Q. P. (2004) Docking studies and model development of tea polyphenol proteasome inhibitors: applications to rational drug design. Proteins: Structure, Function, and Bioinformatics, 54, 58-70.
31. Sun, J., Nam, S., Lee, C. S., Li, B., Coppola, D., Hamilton, A. D. et al. (2001). CEP1612, a dipeptidyl proteasome inhibitor, induces p21WAF1 and p27KIP1 expression and apoptosis and inhibits the growth of the human lung adenocarcinoma A-549 in nude mice. Cancer Res. 61, 1280-4.